Search results for " Recurrence"

showing 10 items of 534 documents

The VEGF/VEGF-R Axis in Sporadic Vestibular Schwannomas Correlates with Irradiation and Disease Recurrence

2012

<b><i>Background/Aims:</i></b> The molecular mechanisms downstream of mutated neurofibromatosis type 2 (NF2) gene resulting in the growth and development of vestibular schwannoma (VS) are controversial. Several lines of evidence suggest the involvement of the vascular endothelial growth factor (VEGF) pathway in VS development. Given that recent studies of VEGF blockade in patients with NF2-associated VS showed positive effects on VS growth control, we initiated this comprehensive study of the VEGF pathway in sporadic VS. <b><i>Methods:</i></b> A tissue microarray analysis of 182 sporadic VS was conducted. The expression of VEGF and its recepto…

AdultMaleVascular Endothelial Growth Factor APathologymedicine.medical_specialtyAdolescentYoung Adultchemistry.chemical_compoundNeuropilin 1medicineHumansNeurofibromatosis type 2ReceptorAgedCell ProliferationCell growthbusiness.industryNeuroma AcousticMiddle Agedmedicine.diseaseNeuromaImmunohistochemistryVascular Endothelial Growth Factor Receptor-2Neuropilin-1BlockadeVascular endothelial growth factorReceptors Vascular Endothelial Growth FactorOtorhinolaryngologychemistryTissue Array AnalysisImmunohistochemistryFemaleNeoplasm Recurrence LocalbusinessORL
researchProduct

Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life

2019

The treatment of patients with recurrent and/or metastatic (R/M) salivary gland adenoid cystic carcinoma (ACC) remains an unmet need.Patients with R/M disease with a history of clinical or symptomatic disease progression within 6 months and a maximum of 1 previous line of chemotherapy or a multiple kinase inhibitor received oral lenvatinib at a dose of 24 mg/day. The primary endpoint was the objective response rate; secondary endpoints included quality of life (QOL) (according to the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 Items [EORTC QLQ-C30] and the European Organization for Research and Treatment of Cancer Quality of Life Question…

AdultMaleadenoid cystic carcinoma; lenvatinib; quality of life; toxicityCancer Researchmedicine.medical_specialtyAdenoid cystic carcinomaAntineoplastic Agentslenvatinib03 medical and health scienceschemistry.chemical_compound0302 clinical medicineSwallowingQuality of lifeInternal medicinemedicineClinical endpointHumansadenoid cystic carcinomaProspective Studies030212 general & internal medicineNeoplasm MetastasisProtein Kinase InhibitorsDose-Response Relationship Drugbusiness.industryPhenylurea CompoundstoxicityCancerCommon Terminology Criteria for Adverse EventsMiddle AgedSalivary Gland Neoplasmsmedicine.diseaseCarcinoma Adenoid CysticSurvival AnalysisSalivary Gland Adenoid Cystic Carcinomaquality of lifeOncologychemistry030220 oncology & carcinogenesisQuinolinesFemaleNeoplasm Recurrence LocalbusinessLenvatinibCancer
researchProduct

2',5'-Oligoadenylate synthetase activity analysis and human papilloma virus typing as prognostic factors in patients with recurrent respiratory papil…

2004

Objective: Determination of early prognostic factors in patients with recurrent respiratory papillomatosis is extremely important, so the major goal of our prospective, multicentre study was to evaluate (1) the feasibility of various factors to determine prognosis of the clinical course,as well as (2) the response to interferon-alpha therapy in recurrent respiratory papillomatosis. Methods: Forty-two patients with recurrent respiratory papillomatosis were treated with interferon-alpha (3 MU/m2 three times per week; mean therapy duration was 2.7 ± 1.8 years)in 1983–1994 and followed-up until 2003. Human papilloma virus (HPV) type, recurrent respiratory papillomatosis severity and 2′,5′-oligo…

AdultMalemedicine.medical_specialtyAdolescent2'-5'-oligoadenylate synthetase activityAntineoplastic AgentsGastroenterologySeverity of Illness IndexVirusMalignant transformationBasal (phylogenetics)Internal medicinemedicine2'5'-Oligoadenylate SynthetaseHumansTypingProspective StudiesChildPapillomaviridaePapillomabusiness.industryInterferon-alphaGeneral Medicinemedicine.diseasePrognosisRespiratory Tract NeoplasmsTreatment OutcomeOtorhinolaryngologyChild PreschoolImmunologyDNA ViralLeukocytes MononuclearPapillomaFemaleRecurrent Respiratory PapillomatosisNeoplasm Recurrence LocalAirwaybusinessThe Journal of laryngology and otology
researchProduct

Use of Interferon-Alpha in Recurrent Respiratory Papillomatosis: 20-Year Follow-up

2005

Objectives: The aim of this study was analysis of the results of use of interferon-α (IFN-α) in patients with recurrent respiratory papillomatosis (RRP) and correlation of the results with human papillomavirus (HPV) type. Methods: A multicenter prospective series (42 patients from 22 hospitals) yielded 20 years of follow-up of patients with RRP and HPV typing who were treated with IFN-α in doses of 3 MU/m2 3 times per week. Results: During long-term follow-up (mean ± SD, 172 ± 36.8 months), the rate of event-free survival evaluated by Kaplan-Meier analysis was 42.8%, and the overall survival rate was 82.6%. The HPV typing revealed an association of HPV 11 with a more aggressive disease cour…

AdultMalemedicine.medical_specialtyAdolescentAlpha interferonAntineoplastic AgentsInjections IntramuscularDisease-Free Survival03 medical and health sciences0302 clinical medicineInternal medicinemedicineAdjuvant therapyHumansDNA Probes HPVProspective StudiesHuman papillomavirusChild030223 otorhinolaryngologyProspective cohort studyLaryngeal NeoplasmsPapillomaviridaeInterferon alfaPapillomabusiness.industryIncidence (epidemiology)InfantInterferon-alphaGeneral MedicineMiddle AgedSurgeryClinical trialTreatment OutcomeOtorhinolaryngologyChild Preschool030220 oncology & carcinogenesisFemaleNeoplasm Recurrence LocalRecurrent Respiratory PapillomatosisbusinessFollow-Up Studiesmedicine.drugAnnals of Otology, Rhinology & Laryngology
researchProduct

Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma

2008

OBJECTIVE: To assess the value of nuclear matrix protein-22 (NMP22), compared with urinary cytology, in predicting the recurrence of bladder cancer that is not transitional cell carcinoma (non-TCC). PATIENTS AND METHODS: We tested the sensitivity, specificity and the predictive accuracy of NMP22 in the context of non-TCC bladder cancer recurrence, and compared it to the performance of urinary cytology. The study group comprised 2687 patients with history of non-muscle-invasive bladder cancer from 10 centres across four continents. RESULTS: The mean patient age was 64.8 years and 75.4% were men; of all patients, 513 (19.1%) had positive urinary cytology, 906 (33.7%) had a positive NMP22 test…

AdultMalemedicine.medical_specialtyAdolescentUrologyUrinary systemUrologyContext (language use)urologic and male genital diseasesSensitivity and SpecificityCohort StudiesPredictive Value of TestsRisk FactorsCytologyBiomarkers TumormedicineCarcinomaHumansChildAgedRetrospective StudiesAged 80 and overGynecologyBladder cancerbusiness.industryNuclear ProteinsMiddle AgedPrognosismedicine.diseaseTransitional cell carcinomaUrinary Bladder NeoplasmsEpidermoid carcinomaPredictive value of testsCarcinoma Squamous CellFemaleNeoplasm Recurrence LocalbusinessBJU International
researchProduct

Radical surgery and different types of urinary diversion in patients with rhabdomyosarcoma of bladder or prostate--a single institution experience.

2013

Abstract Purpose In a retrospective study we analyzed the outcome of patients treated for rhabdomyosarcoma (RMS) of the bladder/prostate with special attention to radical surgery. Methods In 25 patients with genitourinary RMS (15 bladder/10 prostate) the median age at diagnosis was 4 years [1] , [2] , [3] , [4] , [5] , [6] , [7] , [8] , [9] , [10] , [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , and 8 patients had a stage II RMS, 12 stage III and 5 stage IV. In 19/25 (12 bladder/7 prostate), radical surgery and urinary diversion were performed. Urinary diversion comprised 2 continent anal diversions, 11 continent cutaneous diversions, 4 colon conduits and 2 urethral diversions (2 +…

AdultMalemedicine.medical_specialtyAdolescentUrologymedicine.medical_treatmentUrologyAnal CanalUrinary DiversionYoung AdultAntineoplastic Combined Chemotherapy ProtocolsRhabdomyosarcomaMedicineHumansRadical surgeryRhabdomyosarcomaChildCyclophosphamideRetrospective Studiesbusiness.industryGenitourinary systemUrinary diversionUrinary Reservoirs ContinentProstatic NeoplasmsSurgical Stomasmedicine.diseaseAppendixNeck of urinary bladdermedicine.anatomical_structureTreatment OutcomeUrinary Bladder NeoplasmsDoxorubicinVincristineChild PreschoolPediatrics Perinatology and Child HealthDactinomycinFemalePouchNeoplasm Recurrence LocalbusinessComplicationhuman activitiesFollow-Up StudiesJournal of pediatric urology
researchProduct

Juvenile ossifying fibroma of the maxillofacial region: analysis of clinico-pathological features and management

2021

Background The diagnosis and management of juvenile ossifying fibroma (JOF) remains a highly debated topic with paucity of studies with long-term follow-up, hence the aim of this study was to report on the clinico-pathological features and management of these neoplasms. Material and Methods A retrospective analysis was performed on all histopathologically confirmed JOF presenting at two tertiary hospitals in Cape Town, South Africa over a period of 39 years. Clinical, demographic, histopathological and radiological features were analyzed. Surgical methods were documented and a minimum post-operative follow-up of 12 months was a prerequisite. Results Seventeen patients met the inclusion crit…

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentRadiographyBone Neoplasmsmicro-ctSouth AfricaYoung Adultsalivary stonemedicineHumanscbctOstectomyYoung adultChildGeneral DentistryUNESCO:CIENCIAS MÉDICASRetrospective Studiesvolumebusiness.industryResearchMandibleRetrospective cohort studymedicine.diseaseCurettageOtorhinolaryngologysialolithChild PreschoolRadiological weaponFibroma OssifyingFemaleSurgeryRadiologyOral SurgeryNeoplasm Recurrence LocalFibromabusinessMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observation…

2014

Importance The evaluation of therapeutic choices is needed after 24 doses of natalizumab in patients with multiple sclerosis (MS). Objective To evaluate the effect of therapeutic choices on the mean annualized relapse rate and on magnetic resonance imaging MS activity after 24 doses of natalizumab in patients with relapsing-remitting MS. Design, Setting, and Participants The TY-STOP study, which recruited participants between October 22, 2010, and October 22, 2012, at 8 Italian MS centers (secondary care outpatient clinics) among 124 adult patients who demonstrated no clinical or magnetic resonance imaging MS activity after 24 doses of natalizumab. Interventions Natalizumab, no treatment, i…

AdultMalemedicine.medical_specialtyAdult; Antibodies Monoclonal Humanized; Humans; Italy; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis Relapsing-Remitting; Natalizumab; Prospective Studies; Recurrence; Treatment OutcomeAntibodies Monoclonal HumanizedNatalizumabMultiple Sclerosis Relapsing-RemittingRecurrenceInternal medicineClinical endpointmedicineOutpatient clinicHumansProspective StudiesGlatiramer acetateMultiple Sclerosis Ty-STOP Natalizumabbusiness.industryProgressive multifocal leukoencephalopathyNatalizumabMiddle Agedmedicine.diseaseFingolimodMagnetic Resonance ImagingSurgeryDiscontinuationClinical trialTreatment OutcomeItalySettore MED/26 - NeurologiaNeurology (clinical)businessmedicine.drugJAMA neurology
researchProduct

Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study.

2012

Summary.  Background:  Little information is available on the long-term clinical outcome of cerebral vein thrombosis (CVT). Objectives and methods:  In an international, retrospective cohort study, we assessed the long-term rates of mortality, residual disability and recurrent venous thromboembolism (VTE) in a cohort of patients with a first CVT episode. Results:  Seven hundred and six patients (73.7% females) with CVT were included. Patients were followed for a total of 3171 patient-years. Median follow-up was 40 months (range 6, 297 months). At the end of follow-up, 20 patients had died (2.8%). The outcome was generally good: 89.1% of patients had a complete recovery (modified Rankin Scor…

AdultMalemedicine.medical_specialtyAnticoagulant treatment; Cerebral vein thrombosis; Mortality; Recurrence; Adult; Cerebral Veins; Cohort Studies; Female; Humans; Male; Middle Aged; Recurrence; ThrombosisCohort StudiesAnticoagulant treatment; Cerebral vein thrombosis; Mortality; RecurrenceRecurrenceInternal medicinemedicineRisk of mortalityHumansMED/41 - ANESTESIOLOGIAMortalitybusiness.industryIncidence (epidemiology)Cerebral Vein thrombosiHazard ratioCerebral VeinRetrospective cohort studyThrombosisHematologyMiddle Agedmedicine.diseaseThrombosisCerebral VeinsConfidence intervalSurgerycerebral vein thrombosisSettore MED/15 - MALATTIE DEL SANGUEThrombosiCohortFemaleAnticoagulant treatmentCohort StudiebusinessHumanCohort studyJournal of thrombosis and haemostasis : JTH
researchProduct

Therapy for Recurrent High-Grade Gliomas: Results of a Prospective Multicenter Study on Health-Related Quality of Life

2017

Objective To assess the impact of therapy on patients' health-related quality of life (HRQoL) in recurrent high-grade glioma (HGG) in an unselected cohort. Methods In this prospective multicenter study, we analyzed European Organization for Research and Treatment of Cancer Quality of Life core questionnaire and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Brain Neoplasm module questionnaires of 92 patients within 1 year after diagnosis of tumor recurrence of a HGG and respective treatment. We evaluated the influence of re-radiation, second- and third-line chemotherapies, and number of recurrent surgeries on summary scores for functioning, symptoms…

AdultMalemedicine.medical_specialtyBevacizumabAntineoplastic AgentsProcarbazinelaw.inventionCohort StudiesYoung Adult03 medical and health sciences0302 clinical medicineRandomized controlled trialQuality of lifelawSurveys and QuestionnairesInternal medicinemedicineHumansProspective StudiesKarnofsky Performance StatusAgedTemozolomidePerformance statusBrain Neoplasmsbusiness.industryCancerGliomaMiddle Agedmedicine.diseaseEurope030220 oncology & carcinogenesisCohortQuality of LifePhysical therapyFemaleRadiotherapy AdjuvantSurgeryNeurology (clinical)Neoplasm Recurrence Localbusiness030217 neurology & neurosurgerymedicine.drugWorld Neurosurgery
researchProduct